Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
An examination of short-term operating activity ratios reveals several notable trends between 2021 and 2025. Generally, a decrease in efficiency is observed across most metrics in 2022, followed by a period of relative stabilization and slight improvement in some areas towards the end of the analyzed period.
- Inventory Management
- Inventory turnover decreased significantly from 1.25 in 2021 to 0.65 in 2022, indicating a substantial slowdown in the rate at which inventory is sold. This trend persisted, remaining between 0.64 and 0.70 for the subsequent years. Consequently, the average inventory processing period increased dramatically from 292 days in 2021 to 562 days in 2022, and remained elevated, fluctuating between 519 and 572 days through 2025. This suggests a potential build-up of inventory or challenges in effectively managing stock levels.
- Receivables Management
- Receivables turnover experienced a moderate decline from 2.66 in 2021 to 2.28 in 2022, before stabilizing around 2.30 for 2023 and 2024, and then increasing to 2.50 in 2025. The average receivable collection period lengthened from 137 days in 2021 to 160 days in 2022, remaining relatively stable until decreasing to 146 days in 2025. This indicates a slight improvement in collecting receivables towards the end of the period, but collection times remain longer than in 2021.
- Payables Management
- Payables turnover decreased from 4.32 in 2021 to 2.65 in 2022, and then showed some fluctuation, ending at 2.24 in 2025. The average payables payment period increased from 84 days in 2021 to 138 days in 2022, and continued to lengthen, reaching 163 days in 2025. This suggests a trend towards taking longer to pay suppliers.
- Overall Operating Cycle & Cash Conversion
- The operating cycle lengthened considerably from 429 days in 2021 to 722 days in 2022, and remained high, fluctuating between 677 and 732 days before decreasing slightly to 702 days in 2025. The cash conversion cycle followed a similar pattern, increasing from 345 days in 2021 to 584 days in 2022, and remaining elevated, fluctuating between 555 and 586 days before decreasing to 539 days in 2025. These increases indicate that it is taking longer to convert investments in inventory and receivables into cash.
- Working Capital Efficiency
- Working capital turnover decreased from 1.59 in 2021 to 0.96 in 2022, indicating reduced efficiency in utilizing working capital. While there was a slight recovery to 0.97 in 2024, it remained below the 2021 level, reaching 1.05 in 2025. This suggests a less effective use of current assets and liabilities in generating sales.
In summary, the period between 2021 and 2025 was characterized by a general decline in short-term operating efficiency, particularly noticeable in 2022. While some metrics showed slight improvements towards the end of the period, overall performance remained below 2021 levels, suggesting potential areas for operational improvement.
Turnover Ratios
Average No. Days
Inventory Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Cost of revenues | ||||||
| Inventories | ||||||
| Short-term Activity Ratio | ||||||
| Inventory turnover1 | ||||||
| Benchmarks | ||||||
| Inventory Turnover, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Inventory Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Inventory Turnover, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Inventory turnover = Cost of revenues ÷ Inventories
= ÷ =
2 Click competitor name to see calculations.
The inventory turnover ratio demonstrates a declining trend over the five-year period. While cost of revenues fluctuates, inventories consistently increase, contributing to the observed pattern.
- Inventory Turnover Trend
- The inventory turnover ratio decreased from 1.25 in 2021 to 0.65 in 2022, representing a substantial decline. A slight recovery to 0.70 was noted in 2023, but this was followed by a further decrease to 0.64 in 2024. The most recent year, 2025, shows a minimal increase to 0.66, indicating the downward trend has largely stabilized but not reversed.
- Cost of Revenues
- Cost of revenues decreased significantly from US$2,437,500 thousand in 2021 to US$1,560,400 thousand in 2022. Subsequent years show a gradual increase, reaching US$2,100,700 thousand in 2025, but remain below the 2021 level. This fluctuation in cost of revenues does not appear to be directly correlated with the inventory turnover trend.
- Inventory Levels
- Inventories have consistently risen throughout the period, increasing from US$1,951,300 thousand in 2021 to US$3,200,800 thousand in 2025. This continuous growth in inventory, coupled with the fluctuating cost of revenues, is the primary driver of the declining inventory turnover ratio. The largest single-year increase in inventory occurred between 2022 and 2023.
The consistently low and decreasing inventory turnover ratio suggests that the company is becoming less efficient at managing its inventory. A lower ratio indicates that inventory is sitting in storage for a longer period, potentially leading to increased storage costs, obsolescence, and tied-up capital. The stabilization in 2025, while minimal, may warrant further investigation to determine if this represents a potential turning point or simply a temporary pause in the declining trend.
Receivables Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenues | ||||||
| Accounts receivable, net | ||||||
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | ||||||
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Receivables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Receivables Turnover, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Receivables turnover = Revenues ÷ Accounts receivable, net
= ÷ =
2 Click competitor name to see calculations.
The receivables turnover ratio exhibited fluctuations over the five-year period. Initially, the ratio decreased before stabilizing and then increasing slightly. A review of the underlying components, revenues and accounts receivable, provides context for these movements.
- Overall Trend
- The receivables turnover ratio decreased from 2.66 in 2021 to 2.28 in 2022, representing a decline in efficiency of collecting receivables. The ratio remained relatively stable between 2.28 and 2.31 for 2022, 2023, and 2024. A modest increase to 2.50 was observed in 2025, suggesting a potential improvement in receivables collection efficiency.
- Revenue Impact
- Revenues decreased significantly from 2021 to 2022, falling from US$16,071,700 thousand to US$12,172,900 thousand. Revenues then experienced a recovery, increasing to US$13,117,200 thousand in 2023 and continuing to rise to US$14,202,000 thousand in 2024 and US$14,342,900 thousand in 2025. This revenue pattern likely influenced the receivables turnover ratio, particularly the initial decline in 2022.
- Accounts Receivable Impact
- Accounts receivable, net, also decreased from 2021 to 2022, moving from US$6,036,500 thousand to US$5,328,700 thousand. Subsequently, accounts receivable increased to US$5,667,300 thousand in 2023 and further to US$6,211,900 thousand in 2024 before decreasing slightly to US$5,741,100 thousand in 2025. The increase in accounts receivable from 2022 through 2024 partially offset the revenue increases, contributing to the relatively stable receivables turnover ratio during those years.
The increase in the receivables turnover ratio in 2025, coupled with the decrease in accounts receivable, suggests improved efficiency in converting receivables into cash during that period. Further investigation into the company’s credit and collection policies may provide additional insight into these trends.
Payables Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Cost of revenues | ||||||
| Accounts payable | ||||||
| Short-term Activity Ratio | ||||||
| Payables turnover1 | ||||||
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Payables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Payables Turnover, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Payables turnover = Cost of revenues ÷ Accounts payable
= ÷ =
2 Click competitor name to see calculations.
The accounts payable turnover ratio demonstrates a declining trend over the five-year period. Initially, the ratio stood at 4.32 in 2021, but decreased consistently through 2025, reaching 2.24. This suggests a lengthening of the time it takes the company to pay its suppliers.
- Payables Turnover Trend
- A significant decrease in the payables turnover ratio is evident from 2021 to 2022, falling from 4.32 to 2.65. This initial drop represents a substantial change in payment practices or supplier terms. The ratio experienced a modest recovery to 2.99 in 2023, but subsequently declined again to 2.50 in 2024 and further to 2.24 in 2025.
The cost of revenues fluctuated during the period. While decreasing from 2021 to 2022, it increased in subsequent years, reaching 2,100,700 thousand US dollars in 2025. This increase in cost of revenues occurred concurrently with the decreasing payables turnover, potentially indicating that the company is managing higher purchasing volumes with extended payment terms.
- Accounts Payable Trend
- Accounts payable consistently increased throughout the observed period, rising from 564,000 thousand US dollars in 2021 to 939,000 thousand US dollars in 2025. This increase, coupled with the declining payables turnover, suggests the company is utilizing more credit from its suppliers and taking longer to settle those obligations.
The combined effect of increasing accounts payable and decreasing payables turnover suggests a shift in the company’s working capital management. The company appears to be strategically extending its payment terms to suppliers, potentially to improve cash flow or take advantage of early payment discounts, although the latter is not supported by the ratio trend. Further investigation into supplier agreements and payment policies would be necessary to confirm the underlying reasons for these changes.
Working Capital Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Current assets | ||||||
| Less: Current liabilities | ||||||
| Working capital | ||||||
| Revenues | ||||||
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | ||||||
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Working Capital Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Working Capital Turnover, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Working capital turnover = Revenues ÷ Working capital
= ÷ =
2 Click competitor name to see calculations.
The working capital turnover ratio exhibited fluctuating performance over the five-year period. Initial values decreased before stabilizing and showing a slight increase in the most recent year.
- Working Capital Turnover Trend
- The working capital turnover ratio began at 1.59 in 2021, indicating that for every dollar of working capital, the company generated $1.59 in revenue. A substantial decrease was observed in 2022, with the ratio falling to 0.96. This suggests a less efficient utilization of working capital in generating sales during that year.
- The ratio continued to decline in 2023, reaching a low of 0.82. This further reinforces the trend of decreasing efficiency in working capital utilization. However, a modest recovery occurred in 2024, with the ratio increasing to 0.97. This indicates a slight improvement in the relationship between working capital and revenue generation.
- The most recent year, 2025, saw a further increase to 1.05. While still below the initial value in 2021, this represents a positive trend and suggests a strengthening of the link between working capital and revenue.
The observed fluctuations in the working capital turnover ratio correlate with changes in both working capital and revenues. The decrease from 2021 to 2023 coincided with a decrease in revenues in 2022, and an increase in working capital throughout the period. The subsequent stabilization and slight increase in the ratio from 2024 to 2025 align with relatively stable revenues and a decrease in working capital.
- Working Capital and Revenue Relationship
- Working capital increased from $10,082,400 thousand in 2021 to $16,055,800 thousand in 2023, while revenues decreased from $16,071,700 thousand to $13,117,200 thousand over the same period. This divergence contributed to the declining working capital turnover ratio.
- From 2023 to 2025, working capital decreased to $13,653,500 thousand, while revenues increased to $14,342,900 thousand. This shift in the relationship between the two items contributed to the ratio’s stabilization and slight improvement.
Overall, the company experienced a period of declining working capital efficiency, followed by a recent trend towards improvement. Continued monitoring of this ratio, alongside its underlying components, is recommended to assess the sustainability of this positive trend.
Average Inventory Processing Period
Regeneron Pharmaceuticals Inc., average inventory processing period calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Inventory turnover | ||||||
| Short-term Activity Ratio (no. days) | ||||||
| Average inventory processing period1 | ||||||
| Benchmarks (no. days) | ||||||
| Average Inventory Processing Period, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Average Inventory Processing Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Average Inventory Processing Period, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis reveals a significant shift in inventory management efficiency over the observed period. A notable trend is evident in both inventory turnover and the average inventory processing period, indicating changes in how effectively inventory is managed and converted into sales.
- Inventory Turnover
- Inventory turnover decreased substantially from 1.25 in 2021 to 0.65 in 2022. This represents a significant slowdown in the rate at which inventory is sold and replenished. The ratio experienced a slight recovery to 0.70 in 2023, but remained considerably lower than the 2021 level. Further declines were observed in 2024 (0.64) and a marginal increase in 2025 (0.66), suggesting a persistent challenge in efficiently managing inventory levels. The values from 2022 through 2025 remain relatively stable, albeit at a depressed level compared to 2021.
- Average Inventory Processing Period
- The average inventory processing period demonstrates an inverse relationship with inventory turnover. It increased dramatically from 292 days in 2021 to 562 days in 2022, indicating a much longer time required to sell inventory. A decrease to 519 days was noted in 2023, but the period extended again to 572 days in 2024. The most recent period, 2025, shows a slight reduction to 556 days. The consistently high number of days suggests potential issues with inventory obsolescence, overstocking, or inefficiencies in the supply chain. The period remains substantially elevated compared to the 2021 value.
The combined trends in inventory turnover and the average inventory processing period suggest a potential need to re-evaluate inventory management strategies. The substantial increase in the processing period, coupled with the decreased turnover, could indicate challenges in demand forecasting, production planning, or sales execution. Continued monitoring of these ratios is recommended to assess the effectiveness of any implemented corrective actions.
Average Receivable Collection Period
Regeneron Pharmaceuticals Inc., average receivable collection period calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | ||||||
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | ||||||
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Average Receivable Collection Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Average Receivable Collection Period, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average receivable collection period exhibited fluctuations over the five-year period. Initially, the period increased before stabilizing and then decreasing slightly. The receivables turnover ratio demonstrated a similar pattern of initial decline, stabilization, and eventual improvement, which directly influences the collection period.
- Average Receivable Collection Period
- The average receivable collection period increased from 137 days in 2021 to 160 days in 2022. This indicates a lengthening in the time required to collect on credit sales. The period remained relatively stable at 158 and 160 days in 2023 and 2024, respectively, suggesting the longer collection timeframe became consistent. A slight decrease to 146 days was observed in 2025, potentially signaling improved collection efficiency or a change in credit terms.
- Receivables Turnover
- The receivables turnover ratio decreased from 2.66 in 2021 to 2.28 in 2022, aligning with the increase in the average collection period. This suggests a slower rate of converting receivables into cash. The ratio remained relatively consistent at 2.31 and 2.29 in 2023 and 2024. An increase to 2.50 in 2025 was noted, coinciding with the decrease in the average collection period, indicating a faster conversion of receivables to cash.
The observed correlation between the receivables turnover ratio and the average receivable collection period suggests that changes in the company’s credit and collection policies, or broader economic factors impacting customer payment behavior, are influencing both metrics. The slight improvement in both metrics in 2025 warrants further investigation to determine the underlying drivers and assess whether this trend is sustainable.
Operating Cycle
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | ||||||
| Average receivable collection period | ||||||
| Short-term Activity Ratio | ||||||
| Operating cycle1 | ||||||
| Benchmarks | ||||||
| Operating Cycle, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Operating Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Operating Cycle, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle experienced considerable fluctuation over the five-year period. A review of the component ratios reveals the drivers behind these changes.
- Average Inventory Processing Period
- The average inventory processing period demonstrated significant volatility. It increased substantially from 292 days in 2021 to 562 days in 2022. While decreasing to 519 days in 2023, it rose again to 572 days in 2024 before settling at 556 days in 2025. This suggests potential inefficiencies in inventory management or shifts in inventory composition requiring longer processing times. The extended periods could indicate challenges in forecasting demand, managing supply chains, or converting inventory into finished goods.
- Average Receivable Collection Period
- The average receivable collection period exhibited a more moderate trend. It increased from 137 days in 2021 to 160 days in 2022, remaining stable at 160 days in 2023 and 2024. A slight decrease to 146 days was observed in 2025. This indicates a generally stable, though somewhat lengthening, collection process, with a minor improvement in the most recent year. The consistent values suggest established credit and collection policies, with the 2025 reduction potentially reflecting improved collection efficiency.
- Operating Cycle
- The operating cycle, calculated as the sum of the average inventory processing period and the average receivable collection period, mirrored the trends of its components. It increased from 429 days in 2021 to a peak of 722 days in 2022. Subsequent years saw fluctuations, with values of 677 days in 2023, 732 days in 2024, and 702 days in 2025. The overall trend suggests a lengthening of the time required to convert raw materials into cash from sales. The significant increase in 2022, driven by the inventory processing period, had the most substantial impact on the overall operating cycle length.
In summary, the operating cycle lengthened considerably between 2021 and 2024, primarily due to a substantial increase in the average inventory processing period. While the receivable collection period remained relatively stable, the extended inventory processing period significantly impacted the overall cycle length. The slight decrease in the operating cycle in 2025 suggests a potential stabilization, but continued monitoring of inventory management practices is warranted.
Average Payables Payment Period
Regeneron Pharmaceuticals Inc., average payables payment period calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | ||||||
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | ||||||
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Average Payables Payment Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Average Payables Payment Period, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average payables payment period exhibited a consistent upward trend over the five-year period examined. Simultaneously, the payables turnover ratio demonstrated a declining pattern. These movements suggest a lengthening in the time taken to settle obligations to suppliers.
- Payables Turnover
- The payables turnover ratio decreased from 4.32 in 2021 to 2.24 in 2025. This indicates a reduced efficiency in managing and paying off supplier invoices. The most significant decline occurred between 2021 and 2022, followed by a more gradual decrease in subsequent years. A lower ratio suggests the company is taking longer to pay its suppliers, potentially utilizing supplier credit for a longer duration.
- Average Payables Payment Period
- The average payables payment period increased steadily from 84 days in 2021 to 163 days in 2025. This confirms the trend indicated by the payables turnover ratio. The increase was most pronounced between 2022 and 2024, with a further increase observed in 2025. An extended payment period could be a strategic decision to manage cash flow, but it also carries the risk of strained supplier relationships or lost potential discounts for early payment.
- Relationship between Ratios
- The inverse relationship between the payables turnover and the average payables payment period is as expected. As the turnover decreases, the payment period increases, and vice versa. The consistent movement in both metrics reinforces the conclusion that the company is extending the time it takes to pay its suppliers.
Overall, the observed trends suggest a shift in the company’s payables management strategy, potentially driven by changes in working capital needs or supplier negotiations. Further investigation would be required to determine the underlying reasons for these changes and their implications for the company’s financial health and supplier relationships.
Cash Conversion Cycle
Regeneron Pharmaceuticals Inc., cash conversion cycle calculation, comparison to benchmarks
No. days
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | ||||||
| Average receivable collection period | ||||||
| Average payables payment period | ||||||
| Short-term Activity Ratio | ||||||
| Cash conversion cycle1 | ||||||
| Benchmarks | ||||||
| Cash Conversion Cycle, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Cash Conversion Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Cash Conversion Cycle, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The short-term operating activity of the company, as measured by key ratios, exhibits notable fluctuations over the five-year period. The cash conversion cycle, a critical indicator of operational efficiency, demonstrates a complex pattern of lengthening and shortening. A detailed examination of the component ratios reveals the underlying drivers of this trend.
- Average Inventory Processing Period
- The average inventory processing period increased significantly from 292 days in 2021 to 562 days in 2022. While it decreased to 519 days in 2023, it rose again to 572 days in 2024 before slightly declining to 556 days in 2025. This suggests potential inefficiencies in inventory management, with inventory taking considerably longer to process and sell. The substantial increase in 2022 warrants further investigation to determine the cause, such as changes in product mix, supply chain disruptions, or increased inventory holding costs.
- Average Receivable Collection Period
- The average receivable collection period showed a gradual increase from 137 days in 2021 to 160 days in 2022 and remained stable at 158 and 160 days in 2023 and 2024, respectively. A decrease to 146 days is observed in 2025. This indicates a lengthening of the time required to collect payments from customers initially, followed by stabilization and a slight improvement in the most recent year. The initial lengthening could be attributed to changes in credit terms offered to customers or a shift in the customer base.
- Average Payables Payment Period
- The average payables payment period increased from 84 days in 2021 to 138 days in 2022, then decreased to 122 days in 2023, and increased again to 146 days in 2024. It continued to rise to 163 days in 2025. This suggests a fluctuating ability to defer payments to suppliers. The increasing trend in later years could indicate improved negotiation power with suppliers or a deliberate strategy to manage cash flow, but also carries the risk of strained supplier relationships if extended too far.
- Cash Conversion Cycle
- The cash conversion cycle increased substantially from 345 days in 2021 to 584 days in 2022. It then decreased to 555 days in 2023, increased to 586 days in 2024, and finally decreased to 539 days in 2025. This cycle reflects the combined effect of the inventory, receivables, and payables periods. The significant increase in 2022, driven primarily by the increase in the inventory processing period, indicates a longer time between paying for inventory and receiving cash from sales. The subsequent fluctuations suggest ongoing challenges in optimizing working capital management. While the cycle decreased in 2025, it remains significantly higher than in 2021, indicating a continued need for attention to operational efficiency.
Overall, the trends suggest a period of operational disruption followed by attempts at stabilization and improvement. The persistent high inventory processing period remains a key area of concern, and the fluctuations in payables payment period require monitoring to ensure healthy supplier relationships. Further investigation into the drivers behind these trends is recommended to identify opportunities for optimizing working capital and improving cash flow.